Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
AstraZeneca
Express Scripts
McKinsey
McKesson

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for IW-1973

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug IW-1973?

IW-1973 is an investigational drug.

There have been 7 clinical trials for IW-1973. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2017.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Hypertension. The leading clinical trial sponsors are Ironwood Pharmaceuticals, Inc. and [disabled in preview].

There are three US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for IW-1973
TitleSponsorPhase
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male VolunteersIronwood Pharmaceuticals, Inc.Phase 1
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Inhibitor Praliciguat (IW-1973) in Healthy VolunteersIronwood Pharmaceuticals, Inc.Phase 1
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)Ironwood Pharmaceuticals, Inc.Phase 2

See all IW-1973 clinical trials

Clinical Trial Summary for IW-1973

Top disease conditions for IW-1973
Top clinical trial sponsors for IW-1973

See all IW-1973 clinical trials

US Patents for IW-1973

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IW-1973   Start Trial sGC stimulators Ironwood Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
IW-1973   Start Trial sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
IW-1973   Start Trial sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IW-1973

Drugname Country Document Number Estimated Expiration Related US Patent
IW-1973 Australia 2014227862 2033-03-15   Start Trial
IW-1973 Australia 2019203606 2033-03-15   Start Trial
IW-1973 Brazil 112015023349 2033-03-15   Start Trial
IW-1973 Canada 2907111 2033-03-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
AstraZeneca
Merck
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.